Christopher Alvarez‐Breckenridge
YOU?
Author Swipe
View article: EXTH-19. The oncolytic adenovirus Delta-24-RGD achieves antitumor polarization of the chordoma tumor microenvironment in human and murine models of chordoma
EXTH-19. The oncolytic adenovirus Delta-24-RGD achieves antitumor polarization of the chordoma tumor microenvironment in human and murine models of chordoma Open
Chordomas are locally aggressive neoplasms accounting for approximately 20% of primary spinal tumors. Patients experience high rates of disease progression and limited treatment options, highlighting an unmet clinical need and the importan…
View article: EXTH-33. The oncolytic adenovirus RGDOX sensitizes the anti-tumor efficacy of immune checkpoint blockades in murine melanoma brain metastases models
EXTH-33. The oncolytic adenovirus RGDOX sensitizes the anti-tumor efficacy of immune checkpoint blockades in murine melanoma brain metastases models Open
Amongst solid cancers, melanoma brain metastases (MBM) have the highest likelihood of metastasizing to the brain. The use of immune checkpoint inhibitors (ICI) for metastatic melanoma has emerged as first line therapy; however, intracrania…
View article: The kiva system versus balloon kyphoplasty for vertebral compression fracture: a meta-analysis of randomized control trials
The kiva system versus balloon kyphoplasty for vertebral compression fracture: a meta-analysis of randomized control trials Open
View article: Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy
Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy Open
Importance Preoperative stereotactic radiation therapy (SRT) vs postoperative SRT logistics and toxic effects provides clinically significant data on management outcomes. Objective To determine preoperative SRT logistics and safety profile…
View article: Local Control After Adjuvant Radiosurgery for Spinal Metastasis Treated With Decompression and Posterior Segmental Stabilization: A Comparison Between Carbon Fiber/Polyetheretherketone-Based and Metallic Implants
Local Control After Adjuvant Radiosurgery for Spinal Metastasis Treated With Decompression and Posterior Segmental Stabilization: A Comparison Between Carbon Fiber/Polyetheretherketone-Based and Metallic Implants Open
CFRP implants were associated with lower rates of local progression in crude analyses, but did not reach statistical significance in multivariable models. No differences in hardware durability were identified.
View article: Intraoperative ultrasound imaging features in high-grade metastatic spinal cord compression treated with separation surgery
Intraoperative ultrasound imaging features in high-grade metastatic spinal cord compression treated with separation surgery Open
OBJECTIVE The aim of this study was to identify and characterize intraoperative ultrasound (iUS) findings during separation surgery for treatment of high-grade malignant epidural spinal cord compression that correlate with adequate decompr…
View article: Figure S12 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S12 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Effects of TKI withdrawal on vascularization and immune cell infiltration in bone tumors. A) Representative images of bone tumors 12 days following withdrawal of TKIs; tumor (green, GFP), blood vessels (red, laminin) nuclei (blue, DAPI) an…
View article: Figure S10 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S10 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
TKIs’ effect on blood vessels and immune infiltrate in LVRCC67 model. A) Representative images of LVRCC67 bone tumors captured by confocal microscope; tumor cells (green, PAX8), of CD8+ cells (yellow), blood vessels (CD31, red); nuclei (bl…
View article: Figure S6 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S6 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Blood vessel distance analysis in bone tumors. (1) Representative images of bone (VHL- RENCA) tumors captured by confocal microscope; tumor cells (green, GFP); blood vessels (yellow, endomucin; red, laminin), nuclei (blue, DAPI); (2) singl…
View article: Figure S11 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S11 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
In vivo efficacy of TKIs in VHL- RENCA model over 20 days. A, B) Response to TKIs in bone (A) and lung (B) tumors detected by bioluminescence, mean + SEM, n = 8 to 16/group.
View article: Figure S9 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S9 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
CD8+ cell infiltration of lung tumors at baseline and following TKI administration. A) Representative images of CD8+ cells in lung tumors captured by confocal microscope at baseline (no treatment), at day 7, 14 and 21 post-tumor cell injec…
View article: Figure S7 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S7 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Effects of TKIs on bone tumors in UM-RC-3 model. A) Visual representation of the experimental approach. B, C) Neo-angiogenesis in tibiae (B) and quantification (C) of area occupied by blood vessels in tumors; representative images obtained…
View article: Figure S2 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S2 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Osteoclast recruitment and bone disruption. A) RENCA VHL- cells (green, GFP); osteoclasts (red, TRAP); nuclei (blue, DAPI); white arrowhead, TRAP+ cells. Bar, 50 µm; B) UM-RC-3 (green, GFP); osteoclasts (red, TRAP); nuclei (blue, DAPI); wh…
View article: Figure S3 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S3 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Efficacy of TKIs in VHL- RENCA tumors treated at day 14 post-tumor injection. A) Visual representation of the experimental approach. B) Representative images of bioluminescence signal in bones followed by quantification of photon flux, mea…
View article: Figure S8 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S8 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Analysis of CD8+ cell infiltration at baseline in bone tumors and description of COMET analysis. A) Representative images captured by confocal microscope of CD8+ cell infiltration in bone tumors and quantification of CD8+ cell number; tumo…
View article: Figure S1 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S1 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Blood vessel marker expression in bone marrow and tumors. A, B) Detection of bone marrow (A) and tumor (B) blood vessels by confocal acquisition; blue, DAPI; yellow, endomucin; red, laminin; green, tumor GFP; white boxes, magnifications re…
View article: Figure S4 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S4 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Effects of TKIs on blood vessels in RENCA VHL- bone and lung tumors. A) Visual representation of the experimental approach. B,C) Bone tumors: representative pictures captured at the confocal microscope and quantification of blood vessel ar…
View article: Figure S5 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S5 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Cross-sectional slices of tibiae with VHL- RENCA after TKIs treatment. Representative images of bone tumors post- treatment, obtained by confocal microscope: green, GFP; yellow, endomucin; red, laminin; blue, DAPI. Bar, 100 µm. Endo-endomu…
View article: Recurrent<i>ERBB2</i>alterations are associated with esophageal adenocarcinoma brain metastases
Recurrent<i>ERBB2</i>alterations are associated with esophageal adenocarcinoma brain metastases Open
Summary Brain metastases in esophageal adenocarcinoma (EAC) patients are associated with poor prognosis and remain understudied. We performed multi-omics analysis with whole-genome sequencing and single-cell spatial transcriptomics on the …
View article: Recurrent ERBB2 Alterations are Associated with Esophageal Adenocarcinoma Brain Metastases
Recurrent ERBB2 Alterations are Associated with Esophageal Adenocarcinoma Brain Metastases Open
View article: Role of Posterior Carbon Fiber Implants in Spine Tumor Surgery
Role of Posterior Carbon Fiber Implants in Spine Tumor Surgery Open
Study Design Narrative Review. Objective The management of spinal tumors requires a multi-disciplinary approach including surgery, radiation, and systemic therapy. Surgical approaches typically require posterior segmental instrumentation t…
View article: Figure 7 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure 7 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
TKIs as a second-line treatment. A, Schematic representation of experimental design. B, D, and F, Representative images of bioluminescence signal in tibiae/lungs of mice and bioluminescence signal of tumors quan…
View article: Figure 1 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure 1 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Development of ccRCC models in bone. A, WT and KO sequence of the vhl gene of RENCA cells and Western blot analysis of VHL protein expression compared with the housekeeping protein, GAPDH. B, Schematic representation o…
View article: Figure S4 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S4 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Effects of TKIs on blood vessels in RENCA VHL- bone and lung tumors. A) Visual representation of the experimental approach. B,C) Bone tumors: representative pictures captured at the confocal microscope and quantification of blood vessel ar…
View article: Figure S7 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S7 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Effects of TKIs on bone tumors in UM-RC-3 model. A) Visual representation of the experimental approach. B, C) Neo-angiogenesis in tibiae (B) and quantification (C) of area occupied by blood vessels in tumors; representative images obtained…
View article: Figure S10 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S10 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
TKIs’ effect on blood vessels and immune infiltrate in LVRCC67 model. A) Representative images of LVRCC67 bone tumors captured by confocal microscope; tumor cells (green, PAX8), of CD8+ cells (yellow), blood vessels (CD31, red); nuclei (bl…
View article: Figure 6 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure 6 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Prolonged treatment with TKIs followed by withdrawal and survival analysis. A, Schematic representation of experimental design. B, Representative images of bioluminescence signal in tibiae and lungs. C, Bioluminescence…
View article: Figure S12 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S12 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Effects of TKI withdrawal on vascularization and immune cell infiltration in bone tumors. A) Representative images of bone tumors 12 days following withdrawal of TKIs; tumor (green, GFP), blood vessels (red, laminin) nuclei (blue, DAPI) an…
View article: Figure 5 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure 5 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Ex vivo µCT analysis of TKIs’ effects on bone microarchitecture. A, Representative μCT micrographs of tibial metaphysis cross-sections extracted from mice treated with axitinib, cabozantinib, and lenvatinib or vehicle, Bar, 3…
View article: Figure S3 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone
Figure S3 from Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone Open
Efficacy of TKIs in VHL- RENCA tumors treated at day 14 post-tumor injection. A) Visual representation of the experimental approach. B) Representative images of bioluminescence signal in bones followed by quantification of photon flux, mea…